I Take 150 Pills a Day (But This One Is My Workhorse) | Resbiotic : 1513
Summary
Dave Asprey interviews Dr. Vivek Lal about the gut-lung axis and how specific probiotics can enhance respiratory resilience. They discuss how lung microbiome balance reduces inflammation via MMP9 and NLRP3 pathways, potentially mitigating asthma and infection risks. The conversation also covers the dangers of antibiotic overuse, the concept of "air as medicine," and the importance of personal biohacking and self-experimentation for longevity.
Topics discussed
Intro: Breath work, stress, and Zenbud
The Missing Piece: Cellular alignment and gut-lung axis
Discovering the lung microbiome and low biomass
Mechanisms: Inflammation, particle size, and ICU risks
Microaspiration and the gut-lung connection
Antibiotics, germ-free mice, and epigenetics
MMP9, NLRP3, and the future of inhaled probiotics
Sponsors: Caldera skincare and Calroy supplements
Oysters, MMP9 triggers, and inflammation pathways
NLRP3 inflammasome and biohacking regulation
Self-experimentation and off-label drug use
Telmosartan, microbiome testing, and microbial doping
Breath work, Anulom Vilom, and lung resilience
Mold, biofilms, and inter-kingdom interactions
Resbiotic formulation and clinical trial rigor
Target audiences: Smokers, astronauts, and longevity
Dead bacteria, MCTs, and food vs supplement claims
From lab to market: The inventor's duty and conclusion
Listen ad-free on Castria